Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...
In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and generally well-tolerated treatment for DME with retreatment every 6 months ...
Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...
Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...
Lucentis' main patents are not due to expire ... intervals between dosing - an attractive proposition for patients as injections need to be administered into the eye - but has been affected ...
The green light comes on the back of the phase 3 ARCHWAY trial which showed that Susvimo was equivalent to monthly Lucentis injections at maintaining vision in patients over 40 weeks, with 98% of ...
Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
Historically, the most common treatment for wet macular degeneration (wAMD) involved anti-vascular endothelial growth factor (VEGF) injections, such as Avastin, Lucentis, and Eylea. These drugs work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback